CA Patent

CA2482991A1 — Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof

Assigned to Gilead Colorado Inc · Expires 2003-10-30 · 23y expired

What this patent protects

A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.

USPTO Abstract

A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2482991A1
Jurisdiction
CA
Classification
Expires
2003-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Colorado Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.